Tag: migraine

1. Intravenous eptinezumab-treated participants achieved significantly earlier freedom from headaches and from their most bothersome symptoms compared to placebo in those suffering from an acute migraine attack. 2. No serious adverse events occurred in eptinezumab-treated or placebo-treated participants. Evidence Rating Level: 1 (Excellent) Study Rundown: Patients who suffer from multiple migraines every...
1. Microvascular complications were uncommon but nevertheless observed when individuals with Raynaud’s phenomenon (RP) or scleroderma were treated with Calcitonin-gene related peptide (CGRP) antagonist therapy. 2. Microvascular complications in patients with RP included facial telangiectasia and necrosis of distal phalanges after CGRP antagonists use. Evidence Rating: 2 (Good) Study Rundown: Raynaud’s phenomenon...
1. Rimegepant significantly reduced the mean number of migraine days per month between the last 4 weeks of treatment and the observation period compared to placebo (-4.3 days vs. -3.5 days). 2. Patients in both groups were equally likely to have an adverse event and most events were mild-moderate in...
1. Rimegepant significantly reduced the mean number of migraine days per month between the last 4 weeks of treatment and the observation period compared to placebo (-4.3 days vs. -3.5 days). 2. Patients in both groups were equally likely to have an adverse event and most events were mild-moderate in...
1. In this cohort of women, those who experienced migraines with aura were associated with an increased adjusted incidence rate for major cardiovascular diseases (CVD) compared to those with migraines without aura or no migraines. 2. After diabetes and smoking, migraines with aura were found to have the highest CVD...
1. For patients with medication overuse headache, withdrawal and preventive medication was more effective at reducing headache than other strategy alone. Evidence Rating: 1 (Excellent) Medication overuse headache (MOH) affects more than 60 million people globally and is considerably disabling. Although current guidelines recommend withdrawal of medication and preventive medication usage,...
1. In this multicenter study involving adult patients in the United States with a history of migraine, ubrogepant was shown to be more effective than placebo in providing freedom from pain and alleviating the most bothersome symptom within two hours. 2. Doubling the dosage of ubrogepant resulted in limited efficacy...
1. In this multicenter study involving adult patients in the United States with a history of migraine, ubrogepant was shown to be more effective than placebo in providing freedom from pain and alleviating the most bothersome symptom within two hours. 2. Doubling the dosage of ubrogepant resulted in limited efficacy...
1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo. 2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo. Evidence Rating Level: 1 (Excellent)...
1. Patients with migraine treated with rimegepant during an acute event had resolution of pain and their most bothersome symptoms 2 hours after onset more frequently than patients treated with placebo. 2. Incidence of adverse events were similar for patients treated with either rimegepant or placebo. Evidence Rating Level: 1 (Excellent)...